Recon: Eli Lilly’s obesity pill assisted in weight loss maintenance after injection switch; Takeda’s AI-generated psoriasis therapy sees Phase 3 success

• Amid talk of a brain drain, some scientists leave U.S. behind (STAT)
• We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming (STAT)
• Eli Lilly’s obesity pill helped patients maintain weight loss after switch from injections (STAT)

• Moderna lands CEPI as new backer for its pandemic flu program (Endpoints)
• UK Grapples With Disruption in Supplies of Epidural Infusions (Bloomberg)
• MHRA And HSA Lay UK-Singapore Path To Closer Medtech Harmonization – ‘But SMEs Take Heed’ (MedTech Insight)
• Fragmented Governance Must Be Tackled As Part Of EU Medtech Revision (MedTech Insight)
•  

• Novo files marketing application for next-gen weight-loss drug (Reuters)
• Biotech, growing up, is turning profitable (STAT)
• Takeda's $4B immunology drug achieves first Phase 3 successes (Endpoints)
• After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset (Endpoints)
• Subcutaneous Rybrevant; Kalaris shares nAMD data; Pyxis disappoints (Endpoints)
• Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A (Endpoints)
• Atavistik raises $120M for bleeding disorder, blood cancer drugs (Endpoints)
• Insilico advances Hong Kong IPO, eyes $260M raise with Lilly's support (Endpoints)
• Takeda's AI-crafted psoriasis pill succeeds in late-stage studies (Reuters)
• Pharma Makes Billions From Cancer Drugs. Do They Work? (Bloomberg)

• Calming nerves with a hot wearable (Endpoints)
• XCath targets better brain aneurysm outcomes with robotic approach (MedTech Dive)
• Moon Surgical adds 5G and Wi-Fi to Maestro robots for cloud-based AI (MedTech Dive)
• Robot developers make strides in 2025 (MedTech Dive)
• Medtech Outlook 2026: AI Integration Deepens As M&A Fuels Growth (MedTech Insight)

• Taste no longer trumps all: How functional foods are changing the rules on flavor (Food Dive)
• Brashears is back at the USDA's top food safety post (Food Safety News)

• UnitedHealthcare delays controversial RPM policy change (STAT)
• Hospitals owned by real estate investors more likely to close or go bankrupt (STAT)
• In major effort to end gender-affirming care, Trump administration takes aim at hospitals (STAT)
• What I’ve learned by mapping the impacts of NIH cuts (STAT)
• Medicare enrollees to pay 50% less for some drugs in 2025, report says (Reuters)
• Trump to announce Medicare pilot program to pay for CBD treatments, report says (Reuters)
• Consultant: Medicare Payment Changes May Expand Home Cardiac Monitoring and Reshape RPM Market (MedTech Insight)
• New York Giants team doctor: Clinics offering ‘miracle injections,’ ‘next generation cell therapies’ are selling false hope (STAT)
• Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow (STAT)
• Americans facing soaring health insurance costs may get a lifeline in 2026, experts say (Reuters)